1 Guidance

1 Guidance

1.1 Afatinib is recommended as an option, within its marketing authorisation, for treating adults with locally advanced or metastatic non-small-cell lung cancer only if:

  • the tumour tests positive for the epidermal growth factor receptor tyrosine kinase (EGFR-TK) mutation and

  • the person has not previously had an EGFR-TK inhibitor and

  • the manufacturer provides afatinib with the discount agreed in the patient access scheme.

  • National Institute for Health and Care Excellence (NICE)